Nintedanib in the treatment of interstitial lung disease - the view of a rheumatologist. Nintedanib in the treatment of interstitial lung disease - the view of a rheumatologist
Abstract
Nintedanib is an intracellular inhibitor of tyrosine kinases. At present, it is indicated for treatment of adult patients with idiopathic pulmonary fibrosis.
Systemic sclerosis is a chronic fibrosing connective tissue disease affecting blood vessels, skin, musculoskeletal systém and visceral organs. The results of the SENSCIS trial háve shown that nintedanib was able to slow down progression of systemic sclerosis associated interstitial lung disease by decreasing of annual forced vital capacity rate compared with placebo.
No effect on skin fibrosis or health quality was observed. The safety profile of nintedanib was good and similar to that in the patients with idiopathic pulmonary fibrosis.
The data from the INBUILD trial háve revealed that Progressive fibrosing interstitial lung diseases, regardless of clinical diagnosis, háve a similar pathobiologic mechanism as nintedanib had similar effect, regardless of CT scan changes.